Dopavision Overview

  • Founded
  • 2017
Founded
  • Status
  • Private
  • Employees
  • 17
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $14.3M
Latest Deal Amount
  • Investors
  • 7

Dopavision General Information

Description

Developer of digital therapeutic technology designed to slow down myopia progression in children and adolescents. The company's platform delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth, enabling health professionals to treat myopia with a clinically validated therapy.

Contact Information

Website
www.dopavision.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Therapeutic Devices
Application Software
Primary Office
  • Friedrichstrasse 68
  • 10117 Berlin
  • Germany

Dopavision Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Dopavision Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 14-Jul-2021 $14.3M 000.00 000.00 Completed Clinical Trials - General
2. Seed Round 21-Jun-2019 00.000 00.000 Completed Clinical Trials - General
1. Grant $1.57M Completed Startup
To view Dopavision’s complete valuation and funding history, request access »

Dopavision Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of digital therapeutic technology designed to slow down myopia progression in children and adolescents. The co
Other Healthcare Technology Systems
Berlin, Germany
17 As of 2022
000.00
00.00 0000-00-00
00000000000 000.00

00000000

eprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
00000000000 0000000
Airport City, Israel
00 As of 0000
0000
00000 00000

00000 00

ipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim v
00000 0000000000 0000000000 0000000
Paris, France
00 As of 0000
000.00
00.00 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Dopavision Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NovaSight Venture Capital-Backed Airport City, Israel 00 0000 00000 00000
00000 0000000000 Venture Capital-Backed Paris, France 00 000.00 00000000000 000.00
You’re viewing 2 of 2 competitors. Get the full list »

Dopavision Patents

  • 5

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Dopavision Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3906439-A1 Contact lens for eye Pending 13-Dec-2019 00000000
EP-3634574-A1 System and method to stimulate the optic nerve Pending 08-Jun-2017 0000000000
CA-3066647-A1 System and method to stimulate the optic nerve Pending 08-Jun-2017 0000000000
JP-2020522363-A System and method for stimulating the optic nerve Pending 08-Jun-2017 0000000000
US-20200108272-A1 System and method to stimulate the optic nerve Pending 08-Jun-2017 A61N5/0618
To view Dopavision’s complete patent history, request access »

Dopavision Executive Team (5)

Name Title Board Seat Contact Info
Andreas Balser Chief Technology Officer
Hamed Bahmani Co-Founder & Managing Director
Stefan Zundel Co-Founder & Managing Director
Gabriela Burian Chief Medical Officer
Imane Wild Chief Medical Officer
To view Dopavision’s complete executive team members history, request access »

Dopavision Board Members (5)

Name Representing Role Since
Annegret de Baey-Diepolder MD Seventure Partners Board Member 000 0000
Christian Lautner Ababax Health Board Observer 000 0000
Oliver Reuss Boehringer Ingelheim Venture Fund Board Member & Advisor 000 0000
Rana Lonnen Ph.D Novartis Board Observer 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Dopavision Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dopavision Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Ababax Health Other Minority 000 0000 000000 0
Novartis Corporation Minority 000 0000 000000 0
Seventure Partners Venture Capital Minority 000 0000 000000 0
Boehringer Ingelheim Venture Fund Venture Capital Minority 000 0000 000000 0
Flying Health Accelerator/Incubator Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial